Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension
- PMID: 29622568
- DOI: 10.1183/13993003.02310-2017
Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension
Abstract
Recent reports from worldwide pulmonary hypertension registries show a new demographic picture for patients with idiopathic pulmonary arterial hypertension (IPAH), with an increasing prevalence among the elderly.We aimed to investigate the effects of age and comorbidity on risk stratification and outcome of patients with incident IPAH.The study population (n=264) was categorised into four age groups: 18-45, 46-64, 65-74 and ≥75 years. Individual risk profiles were determined according to a risk assessment instrument, based on the European Society of Cardiology and the European Respiratory Society guidelines. The change in risk group from baseline to follow-up (median 5 months) and survival were compared across age groups. In the two youngest age groups, a significant number of patients improved (18-45 years, Z= -4.613, p<0.001; 46-64 years, Z= -2.125, p=0.034), but no significant improvement was found in the older patient groups. 5-year survival was highest in patients aged 18-45 years (88%), while the survival rates were 63%, 56% and 36% for patients in the groups 46-64, 65-74 and ≥75 years, respectively (p<0.001). Ischaemic heart disease and kidney dysfunction independently predicted survival.These findings highlight the importance of age and specific comorbidities as prognostic markers of outcome in addition to established risk assessment algorithms.
Copyright ©ERS 2018.
Conflict of interest statement
Conflict of interest: C. Hjalmarsson reports personal lecture fees from Actelion Pharmaceuticals Sweden, outside the submitted work. Conflict of interest: G. Rådegran reports unrestricted research grants from Actelion Pharmaceuticals Sweden AB and GlaxoSmithKline, and personal lecture fees from Actelion Pharmaceuticals Sweden AB, Bayer Health Care, GlaxoSmithKline, NordicInfu Care and Sandoz/Novartis; G. Rådegran is, and has been, primary or co-investigator in clinical PAH trials for GlaxoSmithKline, Actelion Pharmaceuticals Sweden AB, Pfizer, Bayer Health Care and United Therapeutics, and has been involved in research advisory boards for Actelion Pharmaceuticals Sweden AB, Bayer Health Care, Eli Lilly and Sanofi-Aventis, outside the submitted work. Conflict of interest: D. Kylhammar reports unrestricted research grants from the Swedish Society of PH in cooperation with Actelion Pharmaceuticals Sweden AB, Pfizer and Bayer Health Care, and personal lecture fees from Actelion Pharmaceuticals Sweden AB and GlaxoSmithKline, outside the submitted work. Conflict of interest: B. Rundqvist has been primary or co-investigator in clinical PAH trials for GlaxoSmithKline, Actelion Pharmaceuticals Sweden AB, Bayer Health Care and United Therapeutics, outside the submitted work. Conflict of interest: M.D. Nisell reports personal lecture fees from Actelion Pharmaceuticals Sweden AB, Pfizer, Bayer Health Care, NordicInfu Care, Novartis, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and Takeda; M.D. Nisell has been the primary or co-investigator in clinical trials for Boehringer Ingelheim, AstraZeneca, Takeda, Novartis and United Therapeutics, and has been involved in research advisory boards for Actelion Pharmaceuticals Sweden AB, Bayer Health Care, NordicInfu Care and GlaxoSmithKline.
Comment in
-
Age, risk and outcomes in idiopathic pulmonary arterial hypertension.Eur Respir J. 2018 May 3;51(5):1800629. doi: 10.1183/13993003.00629-2018. Print 2018 May. Eur Respir J. 2018. PMID: 29724788 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical